Whitehawk Therapeutics Appoints Dr. Margaret Dugan as New Chief Medical Officer

Whitehawk Therapeutics Welcomes Dr. Margaret Dugan as Chief Medical Officer

Whitehawk Therapeutics, Inc., an innovative player in the oncology therapeutics space, appoints Dr. Margaret Dugan as its Chief Medical Officer (CMO), effective December 1, 2025. Dr. Dugan arrives with over three decades of experience in global oncology drug development, particularly excelling in early-stage clinical development and regulatory strategies. Her impressive track record includes overseeing more than twelve Phase 1 programs and securing numerous regulatory approvals for significant oncology therapies, such as capmatinib and ceritinib. This wealth of experience positions Whitehawk to strategically advance its mission of developing advanced antibody-drug conjugate (ADC) cancer treatments.

Dr. Dugan's extensive background, notably her tenure at Novartis, where she led the early development organization, has equipped her with the necessary skills to navigate the complexities of drug development from initial proof-of-concept to comprehensive clinical trials. At Novartis, she not only directed numerous programs but also honed her ability to forge successful pathways through regulatory hurdles. Her subsequent roles, including CMO at Dracen Pharmaceuticals and leadership positions at Schrödinger, further highlight her capabilities in guiding clinical programs effectively through early phases and into later stages of development. This combination of strategic oversight and operational execution is critical as Whitehawk prepares to transition its ADC portfolio into clinical trials.

Under Dr. Dugan's leadership, Whitehawk Therapeutics aims to capitalize on its advanced three-asset ADC portfolio, which is designed to overcome existing limitations in cancer treatment methodologies. The company is committed to leveraging smart target selection and a differentiated ADC profile to deliver next-generation therapies for patients suffering from hard-to-treat cancers. Dr. Dugan's expertise is expected to enhance the design of clinical studies while accelerating the development of impactful cancer therapies, ultimately offering new hope for improved outcomes in oncology.

In addition to her role at Whitehawk, Dr. Dugan's prior achievements underscore the potential for rapid advancement in the company’s clinical programs. Her successful track record of navigating the complexities of early-stage drug development positions Whitehawk to make significant strides in bringing its innovative therapies to market. As the company focuses on enhancing its ADC portfolio, Dr. Dugan’s insights and leadership will be instrumental in shaping the future of cancer treatment.

Whitehawk Therapeutics is poised for a transformative phase with Dr. Dugan at the helm of its medical operations. Her appointment signals the company's commitment to advancing its clinical development efforts and reinforces its goal of delivering breakthrough therapies for oncology patients. With Dr. Dugan’s guidance, Whitehawk is better equipped to navigate the evolving landscape of cancer therapeutics and improve treatment options for those in need.